Device Trial Radar · NCT07312383
Skin Microcirculation in Patients With Lower Limb Atherosclerosis
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Dec 15, 2025
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- ODI Medical ASNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 31, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to explore the ability of the non-invasive device ODI-Tech® to monitor changes in microvascular blood flow in patients with lower limb ischemia undergoing the procedure percutaneous transluminal angioplasty (PTA). Microvascular data from patients and healthy case matched controls at baseline will be compared.15 patients and 15 healthy case matched controls will be enrolled.
Conditions
- Percutaneous Transluminal Angioplasty
- Atherosclerosis of Arteries of the Extremities, Unspecified
Interventions
Examination with the ODI-Tech medical deviceDevice
Diffuse reflectance spectroscopy and computer-assisted microscopy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in skin microvascular oxygen saturation (SmvO2)Time frame: From baseline to 40 days post PTA
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Oslo University Hospital
Oslo, Norway · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.